牛牛AI助理已提取核心訊息
On January 31, 2024, HOOKIPA Pharma Inc. received approval from Nasdaq to transfer the listing of its common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market. This move is part of the company's strategy to regain compliance with Nasdaq's minimum bid price requirement. HOOKIPA Pharma's stock had previously fallen below the $1.00 minimum bid price for 30 consecutive business days, leading to a notification of non-compliance. The company was initially given a 180-day grace period to meet the requirement, which it did not achieve. The transfer to The Nasdaq Capital Market allows HOOKIPA Pharma an additional 180-day period, ending on July 29, 2024, to demonstrate compliance. During this time, the company must maintain a closing bid price of at least $1.00 for 10 consecutive business days. HOOKIPA Pharma has indicated that it may consider a reverse stock split as a potential solution to address the bid price deficiency if necessary. The company's common stock will continue to trade under the ticker symbol 'HOOK'.
On January 31, 2024, HOOKIPA Pharma Inc. received approval from Nasdaq to transfer the listing of its common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market. This move is part of the company's strategy to regain compliance with Nasdaq's minimum bid price requirement. HOOKIPA Pharma's stock had previously fallen below the $1.00 minimum bid price for 30 consecutive business days, leading to a notification of non-compliance. The company was initially given a 180-day grace period to meet the requirement, which it did not achieve. The transfer to The Nasdaq Capital Market allows HOOKIPA Pharma an additional 180-day period, ending on July 29, 2024, to demonstrate compliance. During this time, the company must maintain a closing bid price of at least $1.00 for 10 consecutive business days. HOOKIPA Pharma has indicated that it may consider a reverse stock split as a potential solution to address the bid price deficiency if necessary. The company's common stock will continue to trade under the ticker symbol 'HOOK'.
2024年1月31日，HOOKIPA Pharma Inc.獲得納斯達克批准，將其普通股的上市從納斯達克全球精選市場轉移到納斯達克資本市場。此舉是該公司恢復遵守納斯達克最低出價要求的戰略的一部分。HOOKIPA Pharma的股票此前已連續30個工作日跌破1.00美元的最低出價，這導致了違規通知。該公司最初有180天的寬限期來滿足該要求，但它沒有實現這一要求。向納斯達克資本市場的轉讓允許HOOKIPA Pharma再有180天的時間來證明合規性，該期限將於2024年7月29日結束。在此期間，公司必須連續10個工作日將收盤價維持在至少1.00美元。HOOKIPA Pharma表示，如有必要，它可能會考慮將反向股票拆分作爲解決出價缺陷的潛在解決方案。該公司的普通股將繼續以股票代碼 “HOOK” 進行交易。
2024年1月31日，HOOKIPA Pharma Inc.獲得納斯達克批准，將其普通股的上市從納斯達克全球精選市場轉移到納斯達克資本市場。此舉是該公司恢復遵守納斯達克最低出價要求的戰略的一部分。HOOKIPA Pharma的股票此前已連續30個工作日跌破1.00美元的最低出價，這導致了違規通知。該公司最初有180天的寬限期來滿足該要求，但它沒有實現這一要求。向納斯達克資本市場的轉讓允許HOOKIPA Pharma再有180天的時間來證明合規性，該期限將於2024年7月29日結束。在此期間，公司必須連續10個工作日將收盤價維持在至少1.00美元。HOOKIPA Pharma表示，如有必要，它可能會考慮將反向股票拆分作爲解決出價缺陷的潛在解決方案。該公司的普通股將繼續以股票代碼 “HOOK” 進行交易。
有用
沒用